Mekanistic Therapeutics
Led by cancer research pioneers, MEKanistic is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window by inhibiting compensatory resistance pathways at the same time, avoiding inherent toxicity challenges of multi-compound treatments.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
7
1 to 10 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
0
tools in use
Monthly traffic
17
organic / mo
Sign up free to see all 5 verified contacts at Mekanistic Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- JP
Jacob Petersburg
Business Development Manager · Sales & Business Development
EmailPhone - CW
Christopher Whitehead
', · Other
EmailPhone - DC
Danny Cunagin
Chief Executive Officer · Other
EmailPhone - ZW
Zoe Werner
Chief of Staff · Operations
EmailPhone
Showing 4 of 5 verified contacts
Top roles at Mekanistic Therapeutics
5 distinct titles indexed · top 5 shown.
- 1',
- 1business development manager
- 1chief executive officer
- 1chief of staff
- 1co-founder and cso
Sign up to unlock all 5 contacts at Mekanistic Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Mekanistic Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.